메뉴 건너뛰기




Volumn 61, Issue 2, 2008, Pages 335-343

Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: Analysis of 3,758 patients

Author keywords

Adverse events; Capecitabine; Gastric cancer; Renal function; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; HEMOGLOBIN;

EID: 36349019719     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0595-4     Document Type: Article
Times cited : (20)

References (37)
  • 1
    • 0029835349 scopus 로고    scopus 로고
    • Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
    • Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Kato T, Fukushima M (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
    • (1996) Anticancer Drugs , vol.7 , pp. 548-557
    • Shirasaka, T.1    Shimamato, Y.2    Ohshimo, H.3    Yamaguchi, M.4    Kato, T.5    Kato, T.6    Fukushima, M.7
  • 2
    • 0034029776 scopus 로고    scopus 로고
    • Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. for the S-1 Cooperative Gastric Cancer Study Group
    • Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58:191-197
    • (2000) Oncology , vol.58 , pp. 191-197
    • Koizumi, W.1    Kurihara, M.2    Nakano, S.3    Hasegawa, K.4
  • 3
    • 0032189218 scopus 로고    scopus 로고
    • Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients
    • Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720
    • (1998) Eur J Cancer , vol.34 , pp. 1715-1720
    • Sakata, Y.1    Ohtsu, A.2    Horikoshi, N.3    Sugimachi, K.4    Mitachi, Y.5    Taguchi, T.6
  • 6
    • 0034830598 scopus 로고    scopus 로고
    • Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions
    • Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T (2001) Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 12:1133-1137
    • (2001) Ann Oncol , vol.12 , pp. 1133-1137
    • Yamada, Y.1    Shirao, K.2    Ohtsu, A.3    Boku, N.4    Hyodo, I.5    Saitoh, H.6    Miyata, Y.7    Taguchi, T.8
  • 8
    • 18544367472 scopus 로고    scopus 로고
    • Current status and future prospects of chemotherapy for metastatic gastric cancer: A review
    • Ohtsu A (2005) Current status and future prospects of chemotherapy for metastatic gastric cancer: a review. Gastric Cancer 8:95-102
    • (2005) Gastric Cancer , vol.8 , pp. 95-102
    • Ohtsu, A.1
  • 15
    • 15444363796 scopus 로고    scopus 로고
    • Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
    • Nagashima F, Ohtsu A, Yoshida S, Ito K (2005) Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer. Gastric Cancer 8:6-11
    • (2005) Gastric Cancer , vol.8 , pp. 6-11
    • Nagashima, F.1    Ohtsu, A.2    Yoshida, S.3    Ito, K.4
  • 16
    • 0007605328 scopus 로고    scopus 로고
    • Adverse drug reaction criteria of the Japan Society of Clinical Oncology
    • Japan Society of Clinical Oncology
    • Japan Society of Clinical Oncology (1997) Adverse drug reaction criteria of the Japan Society of Clinical Oncology. Int J Clin Oncol 2:177-179
    • (1997) Int J Clin Oncol , vol.2 , pp. 177-179
  • 17
    • 0016916438 scopus 로고
    • Prediction of creatinine clearance from serum creatinine
    • Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41
    • (1976) Nephron , vol.16 , pp. 31-41
    • Cockcroft, D.W.1    Gault, M.H.2
  • 24
    • 0031060433 scopus 로고    scopus 로고
    • Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats
    • Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39:205-211
    • (1997) Cancer Chemother Pharmacol , vol.39 , pp. 205-211
    • Takechi, T.1    Nakano, K.2    Uchida, J.3    Mita, A.4    Toko, K.5    Takeda, S.6    Unemi, N.7    Shirasaka, T.8
  • 25
    • 0141841803 scopus 로고    scopus 로고
    • Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil
    • Yamada Y, Hamaguchi T, Goto M, Muro K, Matsumura Y, Shimada Y, Shirao K, Nagayama S (2003) Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil. Br J Cancer 89:816-820
    • (2003) Br J Cancer , vol.89 , pp. 816-820
    • Yamada, Y.1    Hamaguchi, T.2    Goto, M.3    Muro, K.4    Matsumura, Y.5    Shimada, Y.6    Shirao, K.7    Nagayama, S.8
  • 26
    • 0037570623 scopus 로고    scopus 로고
    • S-1 in gastric cancer: A comprehensive review
    • Suppl 1
    • Maehara Y (2003) S-1 in gastric cancer: a comprehensive review. Gastric Cancer 6(Suppl 1):2-8
    • (2003) Gastric Cancer , vol.6 , pp. 2-8
    • Maehara, Y.1
  • 27
    • 33745929348 scopus 로고    scopus 로고
    • Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers
    • Ajani J (2006) Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. Cancer 107:221-231
    • (2006) Cancer , vol.107 , pp. 221-231
    • Ajani, J.1
  • 30
    • 0023187085 scopus 로고
    • Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile
    • Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203-2206
    • (1987) Cancer Res , vol.47 , pp. 2203-2206
    • Heggie, G.D.1    Sommadossi, J.P.2    Cross, D.S.3    Huster, W.J.4    Diasio, R.B.5
  • 31
    • 0014834207 scopus 로고
    • Biochemical basis for fluorouracil neurotoxicity. the role of Krebs cycle inhibition by fluoroacetate
    • Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155-160
    • (1970) Arch Neurol , vol.23 , pp. 155-160
    • Koenig, H.1    Patel, A.2
  • 32
    • 0027472160 scopus 로고
    • The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy
    • Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71:493-509
    • (1993) Cancer , vol.71 , pp. 493-509
    • Robben, N.C.1    Pippas, A.W.2    Moore, J.O.3
  • 34
    • 0038579652 scopus 로고    scopus 로고
    • Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. a trial performed by the EORTC Early Clinical Studies Group (ECSG)
    • EORTC Early Clinical Studies Group
    • Chollet P, Schöffski P, Weigang-Köhler K, Schellens JH, Cure H, Pavlidis N, Grünwald V, De Boer R, Wanders J, Fumoleau P; EORTC Early Clinical Studies Group (2003) Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39:1264-1270
    • (2003) Eur J Cancer , vol.39 , pp. 1264-1270
    • Chollet, P.1    Schöffski, P.2    Weigang-Köhler, K.3    Schellens, J.H.4    Cure, H.5    Pavlidis, N.6    Grünwald, V.7    De Boer, R.8    Wanders, J.9    Fumoleau, P.10
  • 36
    • 33646591539 scopus 로고    scopus 로고
    • Disparities in gastric cancer chemotherapy between the East and West
    • Ohtsu A, Yoshida S, Saijo N (2006) Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol 24:2188-2196
    • (2006) J Clin Oncol , vol.24 , pp. 2188-2196
    • Ohtsu, A.1    Yoshida, S.2    Saijo, N.3
  • 37
    • 1542269125 scopus 로고    scopus 로고
    • The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors
    • Schöffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15:85-106
    • (2004) Anticancer Drugs , vol.15 , pp. 85-106
    • Schöffski, P.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.